Abstract
ment of the potential and development times of novel technologies for industrial biotechnology. Switzerland has traditionally invested into speciality products. Biotechnology in Switzerland developed from an originally broader industrial focus, which included for example antibiotic fermentation or biocatalysis for various small molecules. Today, red biotechnology is the area of excellence where Swiss companies thrive and have taken a leading global position – at the cost of industrial biotechnology. Thus, the Swiss Biotechnology Association (SBA) carried out a number of surveys in collaboration with the SGCI (Swiss Society of Chemical Industries) and SIBC (Swiss Industrial Biocatalysis Consortium). The goal of this survey and analysis was to track opportunities and challenges, based on which an eventual action plan will be developed. In parallel, Lonza has established a corporate initiative called LIFT (Lonza Innovation for Future Technologies). This programme, with an annual budget of up to 20 million Swiss Francs, funds the search for radically new approaches and ideas (internal and external!) to improve manufacturing and products. This presentation will inform the participant on key findings of all these activities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
